D&D Pharmatech Inc. (KOSDAQ:347850)

D&D Pharmatech Statistics

Total Valuation

D&D Pharmatech has a market cap or net worth of KRW 2.99 trillion. The enterprise value is 2.96 trillion.

Market Cap	2.99T
Enterprise Value	2.96T

Important Dates

The last earnings date was Friday, April 3, 2026.

Earnings Date	Apr 3, 2026
Ex-Dividend Date	n/a

Share Statistics

D&D Pharmatech has 43.54 million shares outstanding. The number of shares has increased by 6.21% in one year.

Current Share Class	43.54M
Shares Outstanding	43.54M
Shares Change (YoY)	+6.21%
Shares Change (QoQ)	+1,193.04%
Owned by Insiders (%)	16.84%
Owned by Institutions (%)	19.11%
Float	34.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	695.94
PB Ratio	37.87
P/TBV Ratio	60.86
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-125.82
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-139.78

Financial Position

The company has a current ratio of 9.41, with a Debt / Equity ratio of 0.08.

Current Ratio	9.41
Quick Ratio	6.43
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	-0.29
Interest Coverage	-72.23

Financial Efficiency

Return on equity (ROE) is -32.29% and return on invested capital (ROIC) is -70.93%.

Return on Equity (ROE)	-32.29%
Return on Assets (ROA)	-21.79%
Return on Invested Capital (ROIC)	-70.93%
Return on Capital Employed (ROCE)	-36.90%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	-921.61M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +594.02% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+594.02%
50-Day Moving Average	81,424.00
200-Day Moving Average	64,146.25
Relative Strength Index (RSI)	48.41
Average Volume (20 Days)	449,005

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, D&D Pharmatech had revenue of KRW 4.30 billion and -23.55 billion in losses. Loss per share was -547.00.

Revenue	4.30B
Gross Profit	4.27B
Operating Income	-33.99B
Pretax Income	-24.90B
Net Income	-23.55B
EBITDA	-28.46B
EBIT	-33.99B
Loss Per Share	-547.00

Balance Sheet

The company has 32.88 billion in cash and 6.24 billion in debt, with a net cash position of 26.64 billion or 611.89 per share.

Cash & Cash Equivalents	32.88B
Total Debt	6.24B
Net Cash	26.64B
Net Cash Per Share	611.89
Equity (Book Value)	78.98B
Book Value Per Share	567.60
Working Capital	45.57B

Cash Flow

In the last 12 months, operating cash flow was -21.14 billion and capital expenditures -64.41 million, giving a free cash flow of -21.20 billion.

Operating Cash Flow	-21.14B
Capital Expenditures	-64.41M
Depreciation & Amortization	5.53B
Net Borrowing	-2.77B
Free Cash Flow	-21.20B
FCF Per Share	-487.04

Margins

Gross Margin	99.40%
Operating Margin	-790.97%
Pretax Margin	-579.42%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

D&D Pharmatech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.21%
Shareholder Yield	-6.21%
Earnings Yield	-0.79%
FCF Yield	-0.71%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on November 13, 2025. It was a forward split with a ratio of 4.

Last Split Date	Nov 13, 2025
Split Type	Forward
Split Ratio	4

Scores

D&D Pharmatech has an Altman Z-Score of 45.96 and a Piotroski F-Score of 2.

Altman Z-Score	45.96
Piotroski F-Score	2